Donor characterization tends to stop at the point where safety is established, which leaves the most useful information unmeasured. Two donors can pass identical screening and carry immune compartments that differ enough to produce different answers to the same experiment. Immunophenotyping is what turns that difference from an unexplained result into a known variable.
What a baseline panel is for
A characterization panel is not diagnostic. Its purpose is to record the composition of the donor’s immune compartment at the time of collection, so that a result observed later can be interpreted against it rather than in isolation.
The value shows up retrospectively, which is why it is so often skipped. Nobody needs the data until an experiment produces something unexpected, and by then the material is consumed and the measurement cannot be made.
The core populations worth recording
| Population | Why it belongs in a baseline |
|---|---|
| CD3+ T cells, with CD4 and CD8 subsets | The ratio varies substantially between donors and shifts most functional readouts |
| CD19+ B cells | Relevant to autoimmune work and to any antibody-related endpoint |
| CD56+ NK cells, with the bright and dim split | Cytotoxic and regulatory populations behave differently, and the ratio is donor-specific |
| CD14+ monocytes | The most fragile major subset, and the one whose frequency shifts most after cryopreservation |
| Memory and naive distribution | Shaped heavily by age and prior infection, and a strong predictor of response |
The NK split deserves particular attention because the two populations do different jobs. A cytotoxicity result and a cytokine result from the same donor can appear contradictory purely because the ratio between them differs from what the analysis assumed.
Related product
Leukopak formats. Single-donor starting material, fresh or cryopreserved, with full donor documentation.
What sits behind the frequencies
Frequencies describe composition. Genotype describes constraint. HLA type determines which peptides a donor can present, which makes it a hard limit on any T cell assay regardless of how many T cells are present. KIR genotype, read against target class I, shapes NK behavior in ways that no NK frequency predicts.
OrganaBio documents high-resolution NGS HLA genotyping across HLA-A, HLA-B, HLA-C, HLA-DR, HLA-DQ and HLA-DP with KIR genotyping as part of the donor program, which is what allows selection on genotype rather than explanation after the fact. The reasoning is set out in KIR genotyping and the HLA typing guide.
Prior exposure is a hidden variable
Cytomegalovirus status is the clearest example. Prior exposure reshapes the T cell and NK compartments substantially and durably, and a donor’s status can move a functional result more than most experimental variables under active study. It is a documented donor attribute rather than something to discover in your data, and it can be used as a selection criterion where availability allows.
Getting the panel to be useful
Record when the phenotyping was performed relative to collection and to cryopreservation, because frequencies shift across both. Keep the gating strategy with the data, since a frequency without its gate is not comparable to anything. And report per donor rather than as a cohort average, because the point of the exercise is the variation.
Material with characterization attached at program level spans leukopaks, cryopreserved PBMCs and isolated T and NK populations. How to read what arrives with it is covered in reading a certificate of analysis.
Frequently asked questions
What is immunophenotyping used for in donor characterization?
It records the composition of a donor’s immune compartment at collection so that later results can be interpreted against a known baseline. Its value is retrospective, which is why it is often skipped until an unexpected result arrives and the material has been consumed.
Which populations belong in a baseline panel?
CD3+ T cells with CD4 and CD8 subsets, CD19+ B cells, CD56+ NK cells split by bright and dim, CD14+ monocytes, and the memory versus naive distribution. Each varies substantially between donors and shifts functional readouts.
Why does the NK bright and dim split matter?
The two populations do different jobs, one predominantly cytotoxic and one predominantly regulatory. A cytotoxicity result and a cytokine result from the same donor can look contradictory purely because that ratio differs from what the analysis assumed.
Is immunophenotyping enough on its own?
No. Frequencies describe composition while genotype describes constraint. HLA type limits which peptides a donor can present regardless of T cell frequency, and KIR genotype shapes NK behavior in ways no NK frequency predicts.
How does cytomegalovirus status affect immune cell material?
Prior exposure reshapes the T cell and NK compartments substantially and durably, often moving a functional result more than the experimental variable under study. It is a documented donor attribute and can be used as a selection criterion where availability allows.
When should phenotyping be performed relative to cryopreservation?
Record when it was done relative to both collection and freezing, because subset frequencies shift across both. A frequency without that timing, and without its gating strategy, is not comparable to anything else.
Should characterization data be averaged across donors?
No. Report per donor. The purpose of the exercise is to make variation visible, and averaging removes exactly the information the panel was run to capture.
Talk to OrganaBio
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
